

Pharmacy & Therapeutics Committee
State of Nevada Department of Health and Human Services
Division of Healthcare Financing and policy
1100 E William St Suite 101
Carson City, NV 89701
rxinfo@dncfp.nv.gov

RE: Annual review, drug class without proposed changes, Atypical Antipsychotics-Oral and Topical; Long-acting Injectables. SSSB Agenda 09/23/2021 (nv.gov)

I understand there will be a review of medications on the PDL at the September 23, 2021, P&T meeting. I am respectfully requesting Rexulti be continued as open access and a preferred drug for the indications of Adjunct treatment for Major Depressive Disorder and Schizophrenia in adult patients.

Rexulti has shown great success in the time that it has been made available to patients as a preferred agent and should continue to be available.

Relapse in symptoms in patients who suffer from Schizophrenia and Depression is detrimental to the community as it increases homelessness, hospitalizations, and use of resources.

Our goal is to maintain PDL status for Rexulti so that as prescribers we can continue to have access to appropriate medication that have proven to be effective in treating these conditions to better help our patients achieve treatment stabilization.

Sincerely,

A handwritten signature in black ink, appearing to read "M. Giddings", written in a cursive style.

Dr. Michelle Giddings, DNP, APRN-BC, PMHNP-BC
Board Certified Psychiatric Nurse Practitioner